2023-507870-42-00RecruitingPhase 2
Evaluation of the Safety and Efficacy of Rimonabant on Cognitive impairment in patients with post-COVID-19 Syndrome.
Effects of a CB1 Receptor Antagonist/Inverse Agonist (Rimonabant) on the Improvement of Cognitive Impairment in Patients with Post-COVID-19 Syndrome (RIMOCOVID-1)
Source: EU CTIS (euclinicaltrials.eu) · Last updated 28 Sept 2026
Brief summary (registry, in English)
To evaluate the efficacy of rimonabant in improving cognitive impairment in patients with post-COVID-19 syndrome compared to placebo.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- First submitted
- 10 Jun 2026
- Start date
- 26 Oct 2026
- Lead sponsor
- Sinfatin S.L.
- Diseases
- Long COVID and ME/CFS
- EU CT number
- 2023-507870-42-00
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 80
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 75 with post-COVID-19 syndrome (long COVID) who have ongoing memory or concentration problems. It compares rimonabant with placebo.
- Age
- 18 to 75 years (both included)
- Sex
- Women and men can join.
- Disease stage
- Active post-COVID-19 syndrome (long COVID), with COVID-19 at least 3 months before joining, ongoing memory or concentration problems, and signs of cognitive impairment in study assessments.
- Earlier treatment
- Must not have taken part in another clinical trial within the last month. Must not take medicines that may interact with the study treatment or that may affect memory or concentration.
- Biomarker or test result
- Brain Fog Scale (BFS) score of 47 or higher.
Main reasons for not taking part
- Active or recent COVID-19 infection
- Severe lung, heart, liver, kidney or bone disease
- Body mass index (BMI) greater than 40 kg/m²
- Major depressive disorder, severe anxiety disorder or other severe mental health condition, or high risk of suicide
- Pregnant or breastfeeding, or able to become pregnant or father a child without effective contraception
Read by machine on 9 Nov 2026.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use substances or medications that may affect memory or concentration.
- Have severe mental health conditions (as per clinical records): major depressive disorder; severe anxiety disorder; bipolar disorder; schizophrenia or schizoaffective disorder; psychotic disorder; previous suicide attempt; any psychiatric disorder requiring psychiatric hospitalization; any other severe psychiatric condition that, in the investigator's opinion, may compromise participant safety or interfere with study
Other illness
- Have an active or recent COVID-19 infection.
- Have other medical conditions that could explain their symptoms.
- Have severe lung, heart, liver, kidney, or bone disease
- Major depressive disorder or severe anxiety disorder, according to DSM-5-TR criteria: Scores ≥ 20 on the BDI-II or ≥ 11 on the HADS at screening, followed by the confirmation of the diagnosis by a health professional (psychologist or psychiatrist).
- Have a known allergy to rimonabant.
- Have neurological conditions that may affect memory or concentration.
Other
- Have a body mass index (BMI) greater than 40 kg/m²
- Are unable to walk or attend study visits.
- Are taking medicines that may interact with the study treatment.
- Have taken part in another clinical trial within the last month.
- Are pregnant or breastfeeding.
- Are able to become pregnant or father a child and are not using effective contraception.
- Have a high risk of suicide.
Who the study is looking for
- Be aged between 18 and 75 years (both inclusive).
- Have had COVID-19 at least 3 months before joining the study.
- Have been diagnosed with active PCS (Long COVID).
- Have ongoing problems with memory or concentration due to long-COVID syndrome.
- Show signs of cognitive impairment in study assessments.
- Be willing to complete study assessments.
- Be able to understand and speak Spanish.
- Provide written consent to participate.
- Indication of brain fog symptoms: BFS (Brain Fog Scale) ≥ 47
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital General Universitario de Albacete | Albacete | Spain | Recruiting |
| Hospital Clínico San Carlos | Madrid | Spain | Recruiting |
| ATHENEA Neuroclinics | San Sebastián | Spain | Recruiting |
| Hospital Nacional De Paraplejicos | Toledo | Spain | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.